Surmodics, Inc. (SRDX): Price and Financial Metrics
SRDX Price/Volume Stats
| Current price | $26.39 | 52-week high | $39.41 |
| Prev. close | $26.52 | 52-week low | $16.79 |
| Day low | $26.39 | Volume | 140,406 |
| Day high | $26.92 | Avg. volume | 57,945 |
| 50-day MA | $29.58 | Dividend yield | N/A |
| 200-day MA | $32.49 | Market Cap | 375.69M |
SRDX Stock Price Chart Interactive Chart >
Surmodics, Inc. (SRDX) Company Bio
SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.
Latest SRDX News From Around the Web
Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.
SurModics (SRDX) Soars 6.2%: Is Further Upside Left in the Stock?SurModics (SRDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
Here's Why You Should Retain Surmodics (SRDX) Stock for NowSurmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock. |
Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH SymposiumEDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York. |
Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposiumEDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York. |
Surmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 91% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Surmodics fair value estimate is US$66.09 Surmodics' US$34.64... |
SRDX Price Returns
| 1-mo | -5.04% |
| 3-mo | -22.31% |
| 6-mo | -10.66% |
| 1-year | 12.11% |
| 3-year | -53.99% |
| 5-year | -34.86% |
| YTD | -27.40% |
| 2023 | 6.54% |
| 2022 | -29.14% |
| 2021 | 10.64% |
| 2020 | 5.04% |
| 2019 | -12.34% |
Continue Researching SRDX
Here are a few links from around the web to help you further your research on Surmodics Inc's stock as an investment opportunity:Surmodics Inc (SRDX) Stock Price | Nasdaq
Surmodics Inc (SRDX) Stock Quote, History and News - Yahoo Finance
Surmodics Inc (SRDX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...